Global Stem Cell Therapy for Osteoarthritis Market Growth (Status and Outlook) 2025-2031

The global Stem Cell Therapy for Osteoarthritis market size is predicted to grow from US$ 41.1 million in 2025 to US$ 208 million in 2031; it is expected to grow at a CAGR of 31.0% from 2025 to 2031.

OA is the most common degenerative joint disease. Its initial symptoms include loss of articular cartilage followed by progressive to joint stiffness, swelling, pain, and loss of mobility. The prevalence rate of OA is extremely high, affecting more than 250 million people worldwide. With increases in the aging and obese populations, the prevalence of OA is predicted to increase to 67 million by 2030. Hence, an effective and safe OA treatment is urgently required.

Stem cells are the body's raw materials — cells from which all other cells with specialized functions are generated. Under the right conditions in the body or a laboratory, stem cells divide to form more cells called daughter cells. These daughter cells either become new stem cells (self-renewal) or become specialized cells (differentiation) with a more specific function, such as blood cells, brain cells, heart muscle cells or bone cells. No other cell in the body has the natural ability to generate new cell types.

The key players of Stem Cell Therapy for Osteoarthritis include Medipost, Theracell Advanced Biotechnology, Nature Cell and Stempeutics. The top 2 manufacturers hold approximately 84% of the global market share.

In terms of product type, Fat Cell is the largest segment, with a share of 94%. And in terms of application, Primary Osteoarthritis has a share about 91 percent.



LPI (LP Information)' newest research report, the “Stem Cell Therapy for Osteoarthritis Industry Forecast” looks at past sales and reviews total world Stem Cell Therapy for Osteoarthritis sales in 2024, providing a comprehensive analysis by region and market sector of projected Stem Cell Therapy for Osteoarthritis sales for 2025 through 2031. With Stem Cell Therapy for Osteoarthritis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Stem Cell Therapy for Osteoarthritis industry.

This Insight Report provides a comprehensive analysis of the global Stem Cell Therapy for Osteoarthritis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Stem Cell Therapy for Osteoarthritis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Stem Cell Therapy for Osteoarthritis market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Stem Cell Therapy for Osteoarthritis and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Stem Cell Therapy for Osteoarthritis.

This report presents a comprehensive overview, market shares, and growth opportunities of Stem Cell Therapy for Osteoarthritis market by product type, application, key players and key regions and countries.

Segmentation by Type:
Fat Cell
Bone Marrow Cell
Others

Segmentation by Application:
Primary Osteoarthritis
Secondary Osteoarthritis

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Medipost
Theracell Advanced Biotechnology
Nature Cell
Stempeutics
Regeneus
Xintela AB
Cells for Cells
CellTex Therapeutics
UCI Health
Magellan
AbelZeta Pharma

Please note: The report will take approximately 2 business days to prepare and deliver.